During the past decade, Middlesex Gastroenterology Associates conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Middlesex Gastroenterology Associates" are "Colitis, Ulcerative" (2 trials) and "Crohn's Disease" (2 trials). Many other conditions were trialed in "Middlesex Gastroenterology Associates" in a lesser frequency.

Most popular intervention types in "Middlesex Gastroenterology Associates" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (1 trials), "Placebo IV" (1 trials), "Placebo SC" (1 trials), "Vedolizumab 108 mg SC" (1 trials) and "Vedolizumab 300 mg IV" (1 trials). Other intervention names were less common.

The vast majority of trials in "Middlesex Gastroenterology Associates" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Middlesex Gastroenterology Associates". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Middlesex Gastroenterology Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Middlesex Gastroenterology Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".